Automate Your Wheel Strategy on IOBT
With Tiblio's Option Bot, you can configure your own wheel strategy including IOBT - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol IOBT
- Rev/Share 0.0129
- Book/Share 0.0242
- PB 71.1779
- Debt/Equity 5.2487
- CurrentRatio 1.9591
- ROIC -4.3145
- MktCap 113315165.0
- FreeCF/Share -1.2659
- PFCF -1.3587
- PE -1.0897
- Debt/Assets 0.1974
- DivYield 0
- ROE -2.8182
- Rating C-
- Score 1
- Recommendation Strong Sell
- P/E Score 1
- DCF Score 4
- P/B Score 1
- D/E Score 1
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| No ratings available. | |||||||
News
IO Biotech's cancer vaccine shows improvement in late-stage study goal
Published: August 11, 2025 by: Reuters
Sentiment: Positive
IO Biotech said on Monday its experimental cancer vaccine, in combination with Merck's Keytruda, showed improvement in a late-stage study goal, but was not statistically significant.
Read More
IO Biotech Announces Clinical Improvement in Progression Free Survival Demonstrated in Pivotal Phase 3 Trial of Cylembio® plus KEYTRUDA® (Pembrolizumab) for the Treatment of First-line Advanced Melanoma, but Statistical Significance Narrowly Missed
Published: August 11, 2025 by: GlobeNewsWire
Sentiment: Neutral
Patients treated with Cylembio (imsapepimut and etimupepimut, adjuvanted) plus pembrolizumab achieved improvement in progression free survival (PFS) compared to patients treated with pembrolizumab monotherapy, HR=0.77 (CI 0.58-1.00), (p=0.056), with median PFS (mPFS) of 19.4 months vs. 11.0 months, respectively; the results on the primary endpoint narrowly missed the study's statistical significance threshold of p≤0.045 In patients enrolled in this study without prior neo-adjuvant/adjuvant anti-PD-1 treatment (n=371), patients treated with Cylembio plus pembrolizumab achieved improvement in PFS, HR: 0.74 (CI 0.56-0.98) (nominal p=0.037), with mPFS of 24.8 months vs.
Read More
IO Biotech, Inc. (IOBT) Just Flashed Golden Cross Signal: Do You Buy?
Published: May 28, 2025 by: Zacks Investment Research
Sentiment: Positive
After reaching an important support level, IO Biotech, Inc. (IOBT) could be a good stock pick from a technical perspective. IOBT recently experienced a "golden cross" event, which saw its 50-day simple moving average breaking out above its 200-day simple moving average.
Read More
IO Biotech Showcases Scientific Leadership Through Cancer Vaccines Educational Session at the American Association for Cancer Research (AACR) Annual Meeting 2025
Published: April 26, 2025 by: GlobeNewsWire
Sentiment: Neutral
NEW YORK, April 26, 2025 (GLOBE NEWSWIRE) -- IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, immune-modulatory, off-the-shelf therapeutic cancer vaccines, today announced that one of its scientific co-founders, Mads Hald Andersen, DMSc, PhD, Director of the National Center for Cancer Immune Therapy (CCIT-DK), chaired and presented at an educational session on cancer vaccines at the 2025 American Association for Cancer Research (AACR) Annual Meeting. The session brought together leading oncology scientists and explored the latest advancements in cancer vaccine research, from preclinical innovation to clinical implementation, providing perspective on the future of cancer vaccines and their potential …
Read More
IO Biotech Presents New Data at AACR 2025 Supporting Dual Mechanism and Immune Activation of Cancer Vaccines IO102-IO103 and IO170
Published: April 25, 2025 by: GlobeNewsWire
Sentiment: Neutral
Preclinical data further support the potential of dual-antigen and TGF-β-directed vaccines to reshape the tumor microenvironment and drive anti-tumor immunity NEW YORK, April 25, 2025 (GLOBE NEWSWIRE) -- IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, immune-modulatory, off-the-shelf therapeutic cancer vaccines, today announced the presentation of new preclinical data for two vaccine candidates developed based on its T-win® platform at the American Association for Cancer Research (AACR) Annual Meeting 2025 in Chicago, Illinois. One poster presentation provides further insights on the mode of action of IO102-IO103, the company's lead investigational therapeutic cancer vaccine which targets cells expressing IDO1 …
Read More
IO Biotech Announces New Preclinical Data for Additional Pipeline Candidate Presented at the AACR-IO Conference
Published: February 23, 2025 by: GlobeNewsWire
Sentiment: Neutral
• Findings support the development of a novel peptide vaccine targeting the immunosuppressive effects of Transforming Growth Beta (TGF- β ) in solid tumors NEW YORK, Feb. 23, 2025 (GLOBE NEWSWIRE) -- IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, immune-modulatory, off-the-shelf therapeutic cancer vaccines, today announced details of its poster presentation at the American Association for Cancer Research (AACR)-IO conference taking place February 23-26, 2025, in Los Angeles, California. Poster Presentation Details Title: A TGF-β-directed peptide vaccine induces T cell activation & drives anti-tumor activity by modulating the architecture of the tumor microenvironment Poster number: B117 Presenter: …
Read More
About IO Biotech, Inc. (IOBT)
- IPO Date 2021-11-05
- Website https://www.iobiotech.com
- Industry Biotechnology
- CEO Mai-Britt Zocca
- Employees 80